Physician profile
Randy Chung
NPI 1427492701
$9,064.02
in general payments reported to CMS, 2019-2025
31 companies · $2,179 in 2025
The $2,179 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65.18 · 2020: $283 · 2021: $984 · 2022: $1,629 · 2023: $1,709 · 2024: $2,215 · 2025: $2,179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,069 · Education: $33.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,069.23 |
| Education | $33.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,648.04 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $1,353.30 | 2020-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $851.91 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $731.74 | 2020-2025 | Xifaxan, Trulance, Relistor |
| Abbott Laboratories | $718.04 | 2022-2024 | Cardiomems |
| Celgene Corporation | $660.15 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $509.78 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $315.14 | 2022-2025 | Dupixent |
| Gilead Sciences, INC. | $260.57 | 2020-2025 | |
| Pfizer INC. | $234.44 | 2022-2025 | |
| Lilly USA, LLC | $229.29 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $164.71 | 2023-2025 | Ibsrela |
| Genzyme Corporation | $155.75 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $152.91 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $152.59 | 2020-2024 | Dificid |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $126.29 | 2024-2025 | Vegzelma, Zymfentra |
| E.R. Squibb & Sons, L.L.C. | $120.93 | 2022 | |
| Janssen Scientific Affairs, LLC | $119.74 | 2022 | |
| Anx Robotica Corp | $104.91 | 2024 | |
| Phathom Pharmaceuticals, INC. | $101.70 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $75.46 | 2021 | |
| Ironwood Pharmaceuticals, INC | $62.75 | 2019-2024 | |
| Evoke Pharma, INC. | $47.99 | 2022-2025 | Gimoti |
| Medtronic, INC. | $40.59 | 2024 | Pillcam, Gi Genius |
| Redhill Biopharma INC. | $39.93 | 2020-2021 | |
| Qol Medical, LLC | $19.31 | 2021 | |
| Braintree Laboratories, INC. | $18.49 | 2020 | |
| Mauna Kea Technologies, INC. | $17.18 | 2024 | |
| Capsovision, INC. | $15.20 | 2025 | Capsocam Plus |
| Novo Nordisk INC | $15.19 | 2025 | Wegovy |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$14,153.01 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randy Chung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.